
Key Takeaways
- Evenity (romosozumab) is a prescription injection for postmenopausal women with osteoporosis who are at high risk for fracture, or who cannot use or have not done well on other osteoporosis medicines.
- Evenity blocks sclerostin, a protein that helps regulate bone building, so the body forms more new bone and, to a lesser extent, breaks down less bone.
- A full course is 12 monthly doses, and each dose is two injections given by a health care provider. A provider may recommend a different osteoporosis medicine afterward to protect the gains.
- Evenity has a boxed warning for heart attack, stroke, and cardiovascular death, so a provider reviews heart history, calcium levels, and dental health before treatment begins.
- Suite Life administer Evenity, Prolia (denosumab), and Prolia biosimilars such as Jubbonti by prescription, and patients with a prescription can request an appointment at Suite Life.
Why Osteoporosis Treatment Matters
Osteoporosis is a condition that weakens bones and makes them more likely to break. Many people do not know they have it until a fracture happens.
According to the National Center for Health Statistics at the Centers for Disease Control and Prevention (CDC), osteoporosis affected about 12.6% of U.S. adults age 50 and older in 2017 to 2018, including 19.6% of women and 4.4% of men. Another 43.1% had low bone mass, a milder loss of bone density that raises the risk of developing osteoporosis later.
There is no cure for osteoporosis, but treatment can help. The Bone Health & Osteoporosis Foundation explains that medicines approved by the U.S. Food and Drug Administration (FDA) can prevent, slow, or stop its progress, and that taking a prescribed medicine along with enough calcium, vitamin D, and regular exercise can help lower the risk of fractures.
What Is Evenity?
Evenity is the brand name for romosozumab-aqqg. It is a monoclonal antibody, which means a lab-made protein designed to target one specific substance in the body. In this case, the target is sclerostin.
The FDA-approved prescribing information for Evenity says Evenity is meant for postmenopausal women with osteoporosis who are at high risk for fracture. The label defines high risk as having had an osteoporotic fracture or having multiple risk factors for fracture. It also covers patients who have not done well on other osteoporosis therapy or cannot take it.
How Evenity Works: Building Bone While Slowing Bone Loss
Bone is living tissue that renews itself all the time. Cells called osteoclasts break down old bone, and cells called osteoblasts build new bone. As people age, more bone can be removed than replaced, which leaves bones weaker.
Osteoporosis medicines fall into two main groups:
| Medicine Type | What It Does | Examples |
|---|---|---|
| Antiresorptive | Slows the breakdown of bone | Bisphosphonates such as alendronate and zoledronic acid, and denosumab (Prolia and Jubbonti) |
| Anabolic | Stimulates new bone formation, | Teriparatide, abaloparatide, and |
| so more bone is built than is lost | romosozumab (Evenity) |
Evenity is classed as an anabolic, or bone-building, medicine. By blocking sclerostin, it increases bone formation. The label adds that it also decreases bone breakdown, though to a lesser extent.
What Studies Showed About Evenity
The label summarizes two large studies in postmenopausal women with osteoporosis.
- Placebo-controlled study of 7,180 women: New spine (vertebral) fractures at 12 months occurred in 0.5% of women who received Evenity, compared with 1.8% of women who received a placebo. After both groups switched to denosumab for a second year, the rates were 0.6% and 2.5%.
- Study of 4,093 women at high risk of fracture: Women who received Evenity for 12 months followed by alendronate had new vertebral fractures in 4.1% of cases through 24 months. For women who took alendronate alone, the rate was 8.0%. Alendronate is an oral osteoporosis medicine.
Fractures outside the spine did not differ significantly between groups at 12 or 24 months in the placebo study. In the alendronate study, Evenity followed by alendronate did lower the risk of nonvertebral fractures compared with alendronate alone.
Who May Be a Candidate for Evenity?
A prescribing provider decides whether Evenity fits, based on each patient's fracture risk and health history. Evenity is approved for postmenopausal women with osteoporosis who:
- Have had an osteoporotic fracture or have multiple risk factors for fracture
- Cannot use other osteoporosis medicines, or did not do well on them
Evenity is not right for everyone. It should not be started in patients who had a heart attack or stroke within the past year. It also should not be given to patients with low blood calcium that has not been corrected, or to patients who have had a serious allergic reaction to it.
Important Safety Information
Evenity carries a boxed warning, which is the strongest warning the FDA requires on a medicine label. It states that Evenity may increase the risk of heart attack, stroke, and death from cardiovascular causes.
In the study that compared Evenity with alendronate, major heart events (cardiovascular death, nonfatal heart attack, and nonfatal stroke) occurred in 2.0% of women taking Evenity and 1.1% of women taking alendronate. In the placebo study, the rate was 0.8% in both groups. If a patient has a heart attack or stroke during treatment, Evenity should be stopped.
Other safety points from the label include:
- Low blood calcium: Patients need enough calcium and vitamin D during treatment, and low calcium must be corrected before the first dose.
- Jaw problems: A rare condition called osteonecrosis of the jaw has been reported. The prescriber examines the mouth before treatment, and patients should tell their dentist they are receiving Evenity.
- Unusual thigh bone fractures: These are rare. Patients should report new or unusual pain in the thigh, hip, or groin.
- Allergic reactions: Rash, hives, or swelling of the face, lips, mouth, tongue, or throat need medical attention right away.
- Common side effects: The most common side effects in studies were joint pain and headache.
How Evenity Compares With Prolia and Jubbonti
Evenity is one of several injections used for osteoporosis. Prolia (denosumab) and Jubbonti (denosumab-bbdz), a biosimilar version of Prolia, are antiresorptive medicines that slow bone breakdown. They are given as one injection every six months, while Evenity is given monthly for a set course of 12 doses. A biosimilar is a biologic medicine that the FDA has found to be highly similar to an approved biologic, with no clinically meaningful differences.
Each medicine has its own benefits, warnings, and schedule. A side-by-side comparison of Evenity, Prolia, and Jubbonti is covered in a companion Suite Life article.
Evenity Treatment at Suite Life
Suite Life provides outpatient injection and infusion services for patients with bone health conditions and works with endocrinologists, rheumatologists, and primary care providers. The team administers Evenity and Prolia, along with FDA-approved Prolia biosimilars such as Jubbonti, by prescription and in line with the referring provider's treatment plan.
Patients receive care in private treatment spaces with recliner seating, Wi-Fi, and light refreshments, and a clinical team monitors each visit. The Suite Life team also helps with scheduling, insurance verification, prior authorization when required, and communication with the prescribing provider.
Learn more about bone health injection and infusion therapy at Suite Life, or see all eight locations across Massachusetts and Rhode Island on the Suite Life homepage. To learn what an outpatient visit looks like, read Suite Life's guide on what to expect at an infusion center.
Ask Your Provider About Evenity, Then Request Your Bone Health Appointment at Suite Life
Evenity offers a time-limited, bone-building approach for postmenopausal women at high risk of fracture, and it comes with heart health considerations that a provider must weigh. Prolia and Jubbonti offer a different path for other patients.
Patients with a prescription for Evenity, Prolia, or a Prolia biosimilar can request an appointment for bone health treatment at Suite Life, and the team will coordinate next steps with the prescribing provider.
Frequently Asked Questions
What is Evenity used for?
Evenity is used to treat osteoporosis in postmenopausal women who are at high risk for fracture. It is also meant for patients who cannot use other osteoporosis medicines or did not do well on them.
Is Evenity an infusion or an injection?
Evenity is an injection under the skin, not an intravenous (IV) infusion. Each monthly dose is two injections given one after the other by a health care provider, for 12 doses.
How is Evenity different from Prolia and Jubbonti?
Evenity builds new bone and slows bone loss, and it is given monthly for 12 months. Prolia and Jubbonti slow bone breakdown and are given as one injection every six months.
What are the main safety concerns with Evenity?
Evenity has a boxed warning for heart attack, stroke, and cardiovascular death. Other concerns include low blood calcium, jaw problems, and unusual thigh bone fractures.
Where can I find Evenity treatment near me in Massachusetts or Rhode Island?
Suite Life serves patients across Massachusetts and Rhode Island. Evenity requires a prescription, and once the order arrives, the Suite Life team contacts the patient to coordinate scheduling, insurance steps, and the best location.